KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $530.8 million.

  • Royalty Pharma's Total Current Liabilities fell 54.55% to $530.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $530.8 million, marking a year-over-year decrease of 54.55%. This contributed to the annual value of $1.3 billion for FY2024, which is 676.82% up from last year.
  • Per Royalty Pharma's latest filing, its Total Current Liabilities stood at $530.8 million for Q3 2025, which was down 56.01% from $1.2 billion recorded in Q2 2025.
  • Royalty Pharma's Total Current Liabilities' 5-year high stood at $1.3 billion during Q4 2024, with a 5-year trough of $124.6 million in Q1 2024.
  • Over the past 3 years, Royalty Pharma's median Total Current Liabilities value was $1.1 billion (recorded in 2023), while the average stood at $756.4 million.
  • As far as peak fluctuations go, Royalty Pharma's Total Current Liabilities tumbled by 88.85% in 2024, and later skyrocketed by 849.52% in 2025.
  • Over the past 5 years, Royalty Pharma's Total Current Liabilities (Quarterly) stood at $171.2 million in 2021, then surged by 581.33% to $1.2 billion in 2022, then tumbled by 86.17% to $161.4 million in 2023, then spiked by 676.82% to $1.3 billion in 2024, then slumped by 54.55% to $530.8 million in 2025.
  • Its Total Current Liabilities was $530.8 million in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.2 billion in Q1 2025.